Boehringer Ingelheim preps FDA submission with new data in rare pediatric lung disease

Ofev was one of Boehringer Ingelheim’s top sellers in the first half of this year, raking in a whopping $1.48 billion. Now the German pharma giant wants to expand into the small group of pediatric patients with lung scarring diseases.